Selected data models

You must log in to select data models for download or further analysis.

16 Search results.
Relevance Rating New first Old first

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Patient Enrollment/ Patient Eligibility - Demographics; General Medical History; Prior Therapy; History of Lymphoma

- 3/18/21 - 1 form, 13 itemgroups, 46 items, 1 language
Itemgroups: Administrative, Demographics (Enrollment), Investigator Signature, For Coulter Use Only, Demographics (General Medical History), Medical History Date, General Medical History, Prior Therapy, Prior Radiation Therapy, History of Lymphoma, Lymphoma Cell Type, Lymphoma Grade , History of Lymphoma
Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Screening - Medical and Surgical History; Disease Stage at Study Entry; Classification of Disease at Study Entry; Cancer related Surgical History; Previous Anti-Neoplastic Therapy

- 2/27/19 - 1 form, 9 itemgroups, 26 items, 1 language
Itemgroups: Adminstrative, Does the subject have any clinically significant medical or surgical history?, Medical and Surgical History, Disease Stage at Study Entry, Classification of Disease at Study Entry, Did the subject have previous cancer related surgical history?, Cancer related Surgical History, Previous Anti-Neoplastic Therapy, Previous Anti-Neoplastic Therapy
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Visit 5 HOMe aFers 1 NCT02905539

- 12/29/17 - 1 form, 12 itemgroups, 49 items, 1 language
Itemgroups: Administrative data, Adverse events, Pre- and concomitant therapy, Questionnaire 1, Questionnaire 2, Questionnaire 3, Vital parameters, Anthropometric Data, Physical Examination, 12-lead ECG, Collection of biological samples_visit 5, Signature for visit 5
Visit 5 form Visite 5 NCT02905539 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Quelle: Prof. Dr. med. Gunnar Heine Universitätsklinikum des Saarlandes

Visit 2 before study drug administration HOMe aFers 1 NCT02905539

- 12/17/17 - 1 form, 11 itemgroups, 33 items, 1 language
Itemgroups: Administrative data, Intercurrent diseases, Concomitant therapy, Questionnaire 1, Questionnaire 2, Questionnaire 3, Vital parameters, Anthropometric Data, 12-lead ECG, Echocardiography, Collection of biological samples_Visit 2_ before study drug administration
Visit 2 before study drug administration form Visite 2 - vor Verabreichung der Studienmedikation NCT02905539 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Quelle: Prof. Dr. med. Gunnar Heine Universitätsklinikum des Saarlandes

Visit 1 Screening Visit HOMe aFers 1 NCT02905539

- 12/17/17 - 1 form, 13 itemgroups, 51 items, 1 language
Itemgroups: Screening visit, Consent for participation in the study, Demographic Data, Medical History, Pre- and concomitant therapy, Questionnaire, Vital parameters, Anthropometric Data, Physical Examination, 12-lead ECG, 24-hour ECG, Collection of biological samples_visit 1, Signature for visit 1 (screening visit)
Visit 1 Screening Visit form NCT02905539 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Quelle: Prof. Dr. med. Gunnar Heine Universitätsklinikum des Saarlandes

Extra Clinic Visit 2 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 7 itemgroups, 41 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Extra Clinic Visit 2

Extra Clinic Visit 3 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 7 itemgroups, 41 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Extra Clinic Visit 3

Extra Clinic Visit 1 GSK Ropinirole Restless Legs Syndrome 101468 - Dose Level 7 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 7 itemgroups, 41 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Extra Clinic Visit 1

Last Clinic Visit GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 7 itemgroups, 40 items, 1 language
Itemgroups: Patient Information, Predose Checklist, RLS Rating Scale, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Last Clinic Visit (Day 49)

Dose Level 8 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 8 itemgroups, 45 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pregnancy Test, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Dose Level 8 (Day 43)

Dose Level 6 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 8 itemgroups, 45 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pregnancy Test, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Dose Level 6 (Day 29)

Dose Level 5 GSK Ropinirole Restless Legs Syndrome 101468

- 9/11/17 - 1 form, 7 itemgroups, 41 items, 1 language
Itemgroups: Patient Information, Predose Checklist, Pre-Dose Vital Signs, Dosing Details, Post-Dose Vital Signs, Adverse Event, Study Protocol
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Dose Level 5 (Day 22)

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial